Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$18.17 USD

18.17
21,017,185

-1.39 (-7.08%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $18.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Novavax, Inc. [NVAX]

Reports for Purchase

Showing records 201 - 220 ( 296 total )

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 201

07/27/2016

Daily Note

Pages: 6

Thinking about Pivotal RSV Data Coming This Quarter; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 202

07/15/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 203

06/27/2016

Company Report

Pages: 6

Putting the Pieces in Place for RSV Awareness Ahead of Pivotal Data; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BLANDING J

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 204

06/27/2016

Company Report

Pages: 6

Novavax Putting the Pieces in Place for RSV Awareness Ahead of Pivotal Data; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 205

06/02/2016

Daily Note

Pages: 5

Leveraging its RSV Knowledge to Retool its Influenza Vaccine and Ease the Path to a Combo Respiratory Vaccine; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 206

05/25/2016

Company Report

Pages: 6

Novavax Fast Track Designation Could Mean a Launch Ahead of 2017 RSV Season; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 207

05/04/2016

Company Report

Pages: 6

Eyes Towards Pivotal Data in 3Q as Novavax Reports 1Q16; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 208

02/29/2016

Company Report

Pages: 5

RSV Trials Up and Running as Novavax Reports 4Q15; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 209

02/16/2016

Company Report

Pages: 9

Prepares for Success with an Eye on Commercialization; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 210

02/16/2016

Company Report

Pages: 9

Novavax Prepares for Success with an Eye on Commercialization; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 211

12/15/2015

Daily Note

Pages: 4

Novavax Executes on Pivotal Trial in the Elderly; Data 3Q16

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 212

11/09/2015

Company Report

Pages: 7

Pivotal Trial Underway as Novavax Reports 3Q15; Reiterate OUTPEFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 213

10/22/2015

Daily Note

Pages: 5

Booster Study up and Running - Up Next, Phase III; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 214

10/22/2015

Daily Note

Pages: 5

Booster Study up and Running - Up Next, Phase III; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 215

10/05/2015

Industry Report

Pages: 6

How Will the Rubble Bounce, or Ideas on the Recent Sell-Off

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 216

10/05/2015

Industry Report

Pages: 6

How Will the Rubble Bounce, or Ideas on the Recent Sell-Off

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 217

09/30/2015

Daily Note

Pages: 5

Focus on the future; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 218

09/11/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 14thThis report contains brief updates on the following: BIOD, CDTX, SGMO, EPZM, LXRX, NVAX, RPTP. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 219

08/28/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of August 31

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 220

08/21/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party